Veritable’s Argos Therapeutics, Inc. ARGS Stock Holding History

Veritable’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-520	Closed	-$51K	–	774
2016 Q4	$51K	Buy	+520	New	+$48.6K	﹤0.01%	734

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Veritable's ARGS Position: Q1 2017 in Review

Veritable sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 520 shares — an estimated $51K sold.

Veritable first reported a position in ARGS in Q4 2016 and held it in 1 quarter. The position peaked at $51K in Q4 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

Veritable reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Veritable sold 520 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $51K.
Veritable first reported a position in Argos Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
Veritable's Argos Therapeutics, Inc. position peaked at $51K in Q4 2016.
43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Veritable's 13F filing for Q1 2017, filed 15 May 2017.